Jeffrey Walsh

Jeffrey Walsh serves as CEO of nChroma Bio, with over 30 years of leadership experience in public and private life sciences companies. He joined nChroma following his tenure as CEO of Nvelop Therapeutics, where he continues to lead the company after its merger with Chroma Medicine. Prior to Nvelop, Jeff was a Venture Partner at Third Rock Ventures and formerly held key executive roles at bluebird bio and Taligen Therapeutics. Earlier, he held positions at Pathogenesis, EXACT Sciences, Allscripts, and SmithKline Beecham, and he currently serves on the boards of Tenaya Therapeutics and Tevard Biosciences. He holds a B.A. from Yale University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.